Halofenate - CAS 26718-25-2

Halofenate is an inhibitor for hypertriglyceridemia, effectively lowering serum triglyceride levels while having minimal impact on serum cholesterol. Additionally, it reduces serum uric acid and promotes uric acid excretion independent of glomerular filtration rate. Halofenate is associated with a significant increase in plasma thyroxine (T4), along with reductions in protein-bound iodine and T4. It can displace T4 from thyroid-binding proteins, which may influence thyroid function in the body.

PPAR, Wnt/beta-catenin

DNA Damage/DNA Repair, Cytoskeletal Signaling, Stem Cells, Metabolism

26691

C19H17ClF3NO4

415.79

O=C(OCCNC(=O)C)C(OC1=CC=CC(=C1)C(F)(F)F)C2=CC=C(Cl)C=C2

-20°C

Ice Packs

Small Compound